| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
112,320,000 |
| Market
Cap: |
48.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4301 - $0.4301 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avalo Therapeutics is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology and rare genetic diseases. Co.'s clinical-stage pipeline include: AVTX-002, which is developing for the treatment of non-eosinophilic asthma, inflammatory bowel disease; AVTX-007, which is developing AVTX-007 for the treatment of Still's Disease; AVTX-801, which is a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency; and AVTX-803, which is a L-fucose substrate replacement therapy for the treatment of LADII.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
79,351 |
662,763 |
| Total Buy Value |
$0 |
$0 |
$272,578 |
$643,635 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
18 |
32 |
| Total Shares Sold |
0 |
0 |
5,291,542 |
5,291,542 |
| Total Sell Value |
$0 |
$0 |
$3,199,077 |
$3,199,077 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
4 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boyd Steven |
Director |
– • • |
2022-01-18 |
4 |
B |
$0.88 |
$182,225 |
I/I |
206,300 |
46,306,300 |
2.25 |
-65% |
|
| Boyd Steven |
Director |
– • • |
2022-01-14 |
4 |
B |
$0.93 |
$78,974 |
I/I |
85,000 |
46,100,000 |
2.25 |
-69% |
|
| Boyd Steven |
Director |
– • • |
2022-01-13 |
4 |
B |
$1.00 |
$314,013 |
I/I |
312,700 |
46,015,000 |
2.25 |
-67% |
|
| Boyd Steven |
Director |
– • • |
2022-01-12 |
4 |
B |
$1.04 |
$59,781 |
I/I |
57,300 |
45,702,300 |
2.25 |
-69% |
|
| Boyd Steven |
Director |
– • • |
2022-01-11 |
4 |
B |
$0.96 |
$15,342 |
I/I |
16,003 |
45,645,000 |
2.17 |
-66% |
|
| Boyd Steven |
Director |
– • • |
2022-01-10 |
4 |
B |
$0.99 |
$484,615 |
I/I |
491,097 |
45,628,997 |
2.25 |
-67% |
|
| Boyd Steven |
Director |
– • • |
2022-01-07 |
4 |
B |
$1.04 |
$142,975 |
I/I |
137,900 |
45,137,900 |
2.25 |
-69% |
|
| Neil Garry Arthur |
Chief Scientific Officer |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$6,699 |
D/D |
4,267 |
85,639 |
2.74 |
-70% |
|
| Greenway Schond L. |
CFO |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$3,503 |
D/D |
2,231 |
3,883 |
2.66 |
-70% |
|
| Harrell James Archie Jr |
Chief Commercial Officer |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$1,716 |
D/D |
1,093 |
36,766 |
2.66 |
-70% |
|
| Sullivan Christopher Ryan |
Chief Accounting Officer |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$1,499 |
D/D |
955 |
9,004 |
2.66 |
-70% |
|
| Wilkins H Jeffrey |
Chief Medical Officer |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$10,002 |
D/D |
6,371 |
33,373 |
2.74 |
-70% |
|
| Boyd Steven |
Director |
– • • |
2021-09-17 |
4 |
B |
$2.20 |
$11,999,999 |
I/I |
5,454,545 |
45,000,000 |
2.25 |
-64% |
|
| Boyd Steven |
Director |
– • • |
2021-09-16 |
4 |
B |
$2.28 |
$341,955 |
I/I |
150,000 |
39,545,455 |
2.25 |
-62% |
|
| Boyd Steven |
Director |
– • • |
2021-09-15 |
4 |
B |
$2.26 |
$215,948 |
I/I |
95,455 |
39,395,455 |
2.25 |
-60% |
|
| Boyd Steven |
Director |
– • • |
2021-08-18 |
4 |
B |
$2.78 |
$55,550 |
I/I |
20,000 |
39,300,000 |
2.25 |
-41% |
|
| Boyd Steven |
Director |
– • • |
2021-08-16 |
4 |
B |
$2.75 |
$82,638 |
I/I |
30,000 |
39,280,000 |
2.25 |
-36% |
|
| Boyd Steven |
10% Owner |
– – • |
2021-08-06 |
4 |
B |
$2.83 |
$70,630 |
I/I |
25,000 |
39,250,000 |
1.5 |
-37% |
|
| Boyd Steven |
10% Owner |
– – • |
2021-08-05 |
4 |
B |
$2.77 |
$69,295 |
I/I |
25,000 |
39,225,000 |
1.5 |
-39% |
|
| Boyd Steven |
10% Owner |
– – • |
2021-08-04 |
4 |
B |
$2.69 |
$268,590 |
I/I |
100,000 |
39,200,000 |
1.5 |
-33% |
|
| Greenway Schond L. |
CFO |
• – – |
2021-06-10 |
4 |
B |
$2.68 |
$1,747 |
D/D |
652 |
1,652 |
2.66 |
-38% |
|
| Harrell James Archie Jr |
Chief Commercial Officer |
• – – |
2021-06-10 |
4 |
B |
$2.28 |
$17,084 |
D/D |
7,493 |
35,673 |
2.74 |
-38% |
|
| Neil Garry Arthur |
Chief Scientific Officer |
• – – |
2021-06-10 |
4 |
B |
$2.28 |
$8,418 |
D/D |
3,692 |
81,372 |
2.74 |
-38% |
|
| Wilkins H Jeffrey |
Chief Medical Officer |
• – – |
2021-06-10 |
4 |
B |
$2.28 |
$2,079 |
D/D |
912 |
27,002 |
2.66 |
-38% |
|
| Boyd Steven |
Director |
– • • |
2021-05-18 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
39,100,000 |
2.17 |
7% |
|
440 Records found
|
|
Page 3 of 18 |
|
|
